Close Menu

NEW YORK – A case study using Natera's personalized circulating tumor DNA monitoring assays has provided insights into the ways that such technology could help oncologists monitor and more precisely treat patients with esophageal cancers.

Although esophageal cancer is not a tumor type with an established use-case for liquid biopsy surveillance right now, there is a growing wave of interest in extending these technologies to the gastrointestinal cancer space, and potentially across other cancer types as well.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.